BioCentury
ARTICLE | Clinical News

ATL101: Phase I data

October 28, 2013 7:00 AM UTC

An open-label, dose-escalation, U.S. Phase I trial in 41 evaluable previously treated patients with metastatic CRPC showed that the recommended Phase II dose of ATL101 - 2 doses of 40-45 mCi/m 2 ATL10...